Doheny Eye Institute, 1355 San Pablo Street, Los Angeles, CA 90033, USA.
Doheny Eye Institute, 1355 San Pablo Street, Los Angeles, CA 90033, USA.
Mitochondrion. 2019 May;46:270-277. doi: 10.1016/j.mito.2018.07.007. Epub 2018 Aug 4.
Leber's hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder characterized by acute bilateral vision loss. The pathophysiology involves reactive oxygen species (ROS), which can be affected by medications. This article reviews the evidence for medications with demonstrated and theoretical effects on mitochondrial function, specifically in relation to increased ROS production. The data reviewed provides guidance when selecting medications for individuals with LHON mutations (carriers) and are susceptible to conversion to affected. However, as with all medications, the proven benefits of these therapies must be weighed against, in some cases, purely theoretical risks for this unique patient population.
Leber 遗传性视神经病变(LHON)是一种母系遗传的线粒体疾病,其特征是急性双侧视力丧失。其病理生理学涉及活性氧(ROS),而 ROS 可受药物影响。本文综述了具有明确和理论上的线粒体功能影响的药物的证据,特别是与增加 ROS 产生有关的药物。所审查的数据为患有 LHON 突变(携带者)和易转为受影响的个体选择药物提供了指导。然而,与所有药物一样,这些治疗方法的已知益处必须与针对这一独特患者群体的某些情况下纯粹理论风险进行权衡。